Day Two @ 14:20
INDUSTRY PHARMACOGENOMICS WORKING GROUPIntroduction to I-PWG and our intent for the workshopIn this introduction, we will describe I-PWG, our composition, mission, and goals. We will describe pharmacogenomics and its importance in drug development, activity within the industry to facilitate the study of pharmacogenomics and the modalities that we leverage to contribute to the development of precision medicines.
Moderator: Michelle Penny
, Senior Director, Head of Computational Biology and GenomicsBiogen Talk 1: Optimizing Pharmacogenomics Sampling in Clinical Trials
: Current Practices for collecting DNA
Hear about current solutions within industry, best practices, and challenges to obtaining PGx populations that are representative of the global clinical trial population.
Presenter: Anita Nelsen,
Head of Genomic Medicine, PAREXEL International Talk 2: NGS and its evolving application in pharmacogenomics Learn how companies are utilizing NGS to inform the discovery and development of safe and effective medicine. Data from an I-PWG survey on NGS practices will be shared.
Presenters: Charles Paulding
, Director Pharmacogenomics, Regeneron Pharmaceuticals, Inc
. and Denit Oz Levi
, Sequencing Analysis & Bioinformatics Expert, Personalized & Predictive Medicine and Big Data Analytics, Teva Talk 3: Closing the knowledge gap: Pharmacogenomics education and resources for the patient, site staff and ethics committeesThis presentation will highlight the need for pharmacogenomics education and describe some of the resources available through I-PWG.
Presenter: Sandra Prucka
, Innovation Lead, Clinical Innovation, Eli Lilly and Company Panel Discussion- Hot topics